Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Venetoclax och azacitidin för behandling av akut myeloid leukemi efter transplantation

30 september 2026 uppdaterad av: M.D. Anderson Cancer Center

En fas II-studie av Venetoclax i kombination med azacitidin vid post-transplantation för AML, T-cellsleukemi och blandad fenotyp akut leukemi

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

1. To determine relapse-free survival after the use of venetoclax in combination with azacitidine given as maintenance therapy or for eradication of minimal residual disease in patients with high risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT).

SECONDARY OBJECTIVES:

  1. To determine the safety and toxicity of venetoclax in combination with azacitidine (type, frequency, severity of adverse events [AEs] and relationship of AEs to venetoclax)
  2. To determine response duration, overall survival.
  3. To determine Incidence of acute and chronic graft versus host disease (GVHD)
  4. To perform matched pairs analysis to obtain bias corrected treatment comparisons of Venetoclax + Vidaza (V+V) to standard therapy in AML patients with no evidence of disease (AML D-) subgroup.

EXPLORATORY OBJECTIVE:

1. To investigate possible relationships between baseline protein and gene expression signatures/mutation profile and BH3 profiling in predicting relapse-free survival time to the combination. This exploratory analysis will be done for the data from the entire study, accounting for the noted biological variables covariates, as well as disease status and whether or not the patient had AML, by fitting a Bayesian time-to-event regression model with RFS the outcome variable.

OUTLINE:

Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine subcutaneously (SC) on days 1-5 and venetoclax orally (PO) once daily (QD) on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Studietyp

Interventionell

Inskrivning (Faktisk)

100

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • M D Anderson Cancer Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Participants 18 to 75 years of age.

  2. English and non-English speaking patients are eligible.

  3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.

    1. AML if they had at least one of the following disease characteristics:

      • Therapy related AML.
      • Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML (see Appendix A.).
      • Primary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis.
      • Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT.
      • Presence of active disease defined as bone marrow blast count >5% at the time of HSCT.
      • Participants transplanted beyond first remission. OR
    2. Biphenotypic or bilineage leukemia (including a myeloid component) OR mixed phenotype acute leukemia (MPAL) OR

    3. Participants with acute lymphoblastic leukemia; B cell or T cell in original.

  4. Participants in morphological remission with no detectable minimal residual disase (MRD) after transplant

  5. Participants who are in remission with no detectable minimal residual disease (MRD) after allogeneic stem cell transplant should have:

    1. Adequate engraftment within 14 days prior to starting study drug:
    2. Absolute neutrophil count (ANC) >/= 1.0 x 109/L without daily use of myeloid growth factor (G-CSF) for at least 7 days; and,
    3. Platelet >/= 30 x 109/L without platelet transfusion within 1 week
    4. Be able to start the drug therapy between 42 to 100 days following HSCT.
  6. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:

    1. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR

    2. Myeloablative regimens including:

      • Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
      • Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
  7. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.

  8. ECOG performance status of 0, 1, or 2.

  9. Serum creatinine </=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation*

  10. Serum bilirubin </= 1.5 x upper limit of normal (ULN).

  11. Aspartate transaminase (AST) or alanine transaminase (ALT) </= 2.5 x ULN.

  12. Alkaline phosphatase </= 2.5 x UL.

  13. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

  14. Negative serum or urine pregnancy test for women with reproductive potential. The only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile. 3.1.2. For cohort #3 and cohort #4 patients (MRD positive cohort):

  1. Participants 18 to 75 years of age.

  2. English and non-English speaking patients are eligible.

  3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow. a. AML OR b. Biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) OR c. Participants with acute lymphoblastic leukemia; B cell or T cell in original.

  4. Persistence or reappearance of MRD by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.

    1. When MRD is detected by flow cytometry, disease level at or above the sensitivity level of the test will be required. • MRD level at or above 0.01% for B cell ALL and T cell ALL.

      • MRD level at or above 0.1% for AML and mixed phenotype acute leukemia.

    2. When MRD is detected by cytogenetics, disease level at or above the sensitivity level of the test will be required.

      • The limited of detection is about 0.25% for males and 0.44% for females.

    3. When MRD is detected by molecular testing, disease level at or above the sensitivity level of the test will be required. • The limited of detection is 0.01%

  5. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:

    a. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR b. Myeloablative regimens including:

    • Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR

    • Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
  6. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.

  7. ECOG performance status of 0, 1, or 2.

  8. Serum creatinine </=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation*

  9. Serum bilirubin </= 1.5 x upper limit of normal (ULN).

  10. Aspartate transaminase (AST) or alanine transaminase (ALT) </= 2.5 x ULN.

  11. Alkaline phosphatase </= 2.5 x UL.

  12. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

  13. Negative serum or urine pregnancy test for women with reproductive potential. The only participants who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile.

Exclusion Criteria:

  1. Active acute GVHD grade II or higher.

  2. Active chronic GVHD that is extensive (see Appendix C.).

  3. Uncontrolled GVHD (see Appendix C.).

  4. Concurrent use of systemic immune suppressive other than calcineurin inhibitors, sirolimus and steroids

  5. Active uncontrolled systemic fungal, bacterial or viral infection.

  6. Active bleeding.

  7. Symptomatic or uncontrolled arrhythmias.

  8. Significant active cardiac disease within the previous 6 months, including:

    1. New York Heart Association (NYHA) class III or IV congestive heart failure see Appendix C.).

    Unstable angina or angina requiring surgical or medical intervention, and/or b. Myocardial infarction.

  9. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).

  10. Prior history of malignancies, other than leukemia, unless the subject has been free of the disease for >/= 1 year. However, participants with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast;
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system).
  11. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (azacitidine, venetoclax)

Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Given PO

Andra namn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto

Given SC

Andra namn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • Onureg

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Relapse-free survival (RFS) time
Tidsram: From the date of first administration of venetoclax + azacitidine (vidaza) (V+V), assessed up to 60 days after last V+V dose

Summary statistics for RFS time will be computed for all patients and within each (disease status, disease type) subgroup. RFS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.

From the date of first administration of venetoclax + azacitidine (vidaza) (V+V), assessed up to 60 days after last V+V dose

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall survival (OS) time
Tidsram: Up to 60 days after last V+V dose

Summary statistics for OS time will be computed for all patients and within each (disease status, disease type) subgroup. OS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.

Up to 60 days after last V+V dose
Incidence of severe (grade 3 or 4) infection
Tidsram: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Graft-versus-host disease
Tidsram: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Incidence of other inter-current adverse events during follow up
Tidsram: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Non-relapse mortality
Tidsram: Within 90 days from the start of V+V treatment

Defined as death from any cause, within 90 days from the start of V+V treatment that is not preceded by disease recurrence. Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Within 90 days from the start of V+V treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Betul Oran, M.D. Anderson Cancer Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 maj 2020

Primärt slutförande (Beräknad)

31 december 2026

Avslutad studie (Beräknad)

31 december 2026

Studieregistreringsdatum

Först inskickad

14 oktober 2019

Först inskickad som uppfyllde QC-kriterierna

14 oktober 2019

Första postat (Faktisk)

16 oktober 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera